Doctors Reveal Shocking ‘Irreversible’ Danger Lurking Behind Ozempic and Mounjaro Use—What You Need to Know Now

Imagine grabbing that magic little pen promising effortless weight loss, only to find out it’s quietly sabotaging your bones and muscles. Sounds like the plot twist nobody ordered, right? Well, doctors are waving giant red flags about popular meds like Ozempic, Mounjaro, and Wegovy—those glamorized GLP-1 agonists initially designed for Type-2 diabetes, now coveted by many chasing the slim dream. But here’s the kicker: beneath the surface, these drugs might be draining not just fat but the very muscle and bone that keep us upright and strutting. From celebrity confessions to hard-hitting warnings from world-renowned experts, the narrative is shifting — could the price of those pounds shed be way steeper than we thought? Hang tight; this story’s a real eye-opener that might just make you rethink your quick-fix plans. LEARN MORE

Doctors have issued a warning about a potentially irreversible side effect that could impact anyone taking the likes of Ozempic, Mounjaro and Wegovy.

Each of the drugs – which are primarily prescribed for those with Type-2 diabetes – contain GLP-1 agonists, which have now been linked to a devastating side effect.

We have already seen the likes of Jeremy Clarkson open up about the terrible impact Ozempic had on his body as he sought to lose weight – despite the drug in particular not being approved for weight loss here in the UK – but that seemingly isn’t putting off more and more of the general public who are turning to these drugs as a surefire way to shed some pounds.

Doctors across the world have already warned about the short-term and long-term complications that can arise from taking medicines such as these, with the pharmaceutical companies behind them also urging the public to get a genuine prescription before taking them.

Doctors are worried about the potential side effect that many have experienced from taking drugs like Ozempic, Mounjaro and Wegovy (Getty Stock Image)

Novo Nordisk, Ozempic’s manufacturer, previously told LADbible Group: “Wegovy®▼ (semaglutide injection) and Ozempic® (semaglutide injection) are prescription only medicines and require a healthcare professional to prescribe under strict supervision.”

But now, doctors and The Royal Osteoporosis Society (ROS) are warning that those who are taking the drugs for illicit reasons could end up losing weight not just in fat, but in vital muscle and bone mass.

Losing this muscle can impair someone’s strength and joint stability, while reduced bone density also raises the risk of osteoporosis, a condition which can cause brittle bones.

Julia Thomson, a specialist nurse with the ROS, told the Sunday Express: “This is an emerging field of research and people need to be warned that using these drugs increases the risk of losing bone and muscle as well as fat.

“Bone and muscle health is key to preventing the risk of falling and fractures which can lead to premature death or else have a devastating effect on people’s ability to live independently.”

Osteoporosis has been linked to the drugs (Getty Stock Image)

It was only recently that singer Avery confirmed she was suffering from the debilitating disease after just one year of taking Ozempic.

Professor Carl Heneghan, director of Oxford University’s Centre for Evidence-Based Medicine, added: “Any drug that reduces muscle mass and bone density is a bad idea for people who are frail and those vulnerable to fractures with osteoporosis.

“The evidence is clear – these drugs carry significant risks and the longer a patient stays on them, the greater the risk.”

Studies also found that women are at an even greater risk of osteoporosis should they take these drugs, as menopause can accelerate bone loss due to a decrease in oestrogen.

Dr. Taher Mahmud, founder of the London Osteoporosis Clinic, concluded: “It is essential that those taking GLP-1 agonists know about the importance of good nutrition and weight-bearing exercise.”

LADbible has contacted the ROS, Novo Nordisk and Eli Lilly for comment.